Skip to main content

Advertisement

Table 3 Measurement of rivaroxaban plasma concentrations

From: Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study

No Delay (h) PT (sec) Biophen® DiXaI (ng/ml) Estimated cc at trough (ng/ml) Clearance (L/h) Potential PK drug interactions Potential PD drug interactions
1 28 18.7 84.8 98 3.3 Ibuprofen
2 22 19.6 237.5 181 a 2.0 Diltiazem (↑), Clarithromycin (↑) Escitalopram
3 38 15.4 70.8 125 a 2.9 Simvastatin (↑) /
4 27 17.7 58.3 69 3.9 Diclofenac, Escitalopram
5 27 N/K 139.4 134 a 2.4 Amiodarone (↑) Aspirin
6 26 12.9 4.9 12 7.9 Amiodarone (↑) /
7 37 14.4 18.3 44 4.8 Diltiazem (↑) /
8 27 15.3 86.5 89 3.0 / /
9 9 26.0 357.8 251 a 3.2 / /
10 13 N/K 184.7 72 3.9 / Duloxetine, Paroxetine
  1. Biophen®DiXaI Biophen® Direct Factor Xa Inhibitors, cc concentration, N/K not known, PD pharmacodynamics, PK pharmacokinetics, PT prothrombin time (normal range: 12.4–14.5 s), ↑: increased plasma concentrations, ↓: decreased plasma concentrations
  2. aEstimated trough concentration above the on-therapy range (we considered higher-than-expected rivaroxaban levels for patient 5, as measured concentration was higher than 136 ng/ml)